[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112016007868A2 - vacinas contra o vírus de epstein-barr - Google Patents

vacinas contra o vírus de epstein-barr

Info

Publication number
BR112016007868A2
BR112016007868A2 BR112016007868A BR112016007868A BR112016007868A2 BR 112016007868 A2 BR112016007868 A2 BR 112016007868A2 BR 112016007868 A BR112016007868 A BR 112016007868A BR 112016007868 A BR112016007868 A BR 112016007868A BR 112016007868 A2 BR112016007868 A2 BR 112016007868A2
Authority
BR
Brazil
Prior art keywords
epstein
ebv
vaccines
barr virus
coated
Prior art date
Application number
BR112016007868A
Other languages
English (en)
Inventor
J Nabel Gary
Cohen Jeffrey
Kanekiyo Masaru
Bu Wei
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of BR112016007868A2 publication Critical patent/BR112016007868A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

as vacinas são fornecidas de modo que extraem anticorpos neutrali-zantes contra o vírus de epstein-barr (ebv). algumas vacinas com-preendem nanopartículas que apresentam proteínas revestidas do ebv na sua superfície. as nanopartículas compreendem proteínas de fusão compreendendo uma subunidade monomérica de uma proteína de auto-montagem, tal como ferritina, unida à pelo menos uma parte de uma proteína revestida do ebv. as proteínas de fusão se auto-agrupam para formar as nanopartículas de apresentação da proteína revestida. tais vacinas podem ser utilizadas para vacinar um indivíduo contra a infecção por diferentes tipos de vírus de epstein-barr, assim como os vírus de epstein-barr que são antigenicamente divergentes do vírus do qual a proteína revestida de ebv foi obtida. também são fornecidas as proteínas de fusão e moléculas de ácido nucléico que codificam tais proteínas.
BR112016007868A 2013-10-11 2014-10-10 vacinas contra o vírus de epstein-barr BR112016007868A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361889840P 2013-10-11 2013-10-11
US201361921284P 2013-12-27 2013-12-27
PCT/US2014/060142 WO2015054639A1 (en) 2013-10-11 2014-10-10 Epstein-barr virus vaccines

Publications (1)

Publication Number Publication Date
BR112016007868A2 true BR112016007868A2 (pt) 2017-12-05

Family

ID=51904224

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007868A BR112016007868A2 (pt) 2013-10-11 2014-10-10 vacinas contra o vírus de epstein-barr

Country Status (5)

Country Link
US (2) US10744199B2 (pt)
EP (2) EP3054971B1 (pt)
CN (1) CN105792842B (pt)
BR (1) BR112016007868A2 (pt)
WO (1) WO2015054639A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013044203A2 (en) 2011-09-23 2013-03-28 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES Novel influenza hemagglutinin protein-based vaccines
WO2015054639A1 (en) 2013-10-11 2015-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epstein-barr virus vaccines
SG11201705264WA (en) 2014-12-31 2017-07-28 The Usa As Represented By The Secretary Detp Of Health And Human Services Novel multivalent nanoparticle-based vaccines
EP3380119B1 (en) * 2015-11-23 2021-08-25 Boehringer Ingelheim Animal Health USA Inc. Fmdv and e2 fusion proteins and uses thereof
FR3050448A1 (fr) * 2016-04-21 2017-10-27 Bioaster Nanoparticules a base d'encapsuline.
CN107344969B (zh) * 2016-05-05 2021-03-05 中国科学院武汉病毒研究所 一种纳米流感疫苗及构建方法和应用
IL303650B1 (en) 2016-09-02 2024-10-01 Us Health Stable group 2 trimers from the stem region of influenza hemagglutinin and their uses
EP3573649A4 (en) * 2017-01-27 2020-12-30 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. VACCINE COMPOSITIONS OF HERPESVIRUS ENVELOPE PROTEIN COMBINATIONS INTENDED TO INDUCE AN IMMUNE RESPONSE
WO2018175518A1 (en) * 2017-03-22 2018-09-27 The Scripps Research Institute Mini-protein immunogens displayng neutralization epitopes for respiratory syncytial virus (rsv)
US20210115113A1 (en) * 2017-04-28 2021-04-22 City Of Hope Epstein-barr virus antibodies and uses thereof
WO2018209125A1 (en) * 2017-05-10 2018-11-15 Fred Hutchinson Cancer Research Center Epstein barr virus antibodies, vaccines, and uses of the same
EP3713601A4 (en) * 2017-11-21 2022-03-09 Modernatx, Inc. VACCINES AGAINST EPSTEIN-BARR VIRUS
US10738090B2 (en) * 2017-12-14 2020-08-11 Lawrence Livermore National Security, Llc Engineered microcompartment protein and related methods and systems of engineering bacterial systems for non-native protein expression and purification
CN111801342A (zh) * 2017-12-20 2020-10-20 葛兰素史密丝克莱恩生物有限公司 爱泼斯坦-巴尔病毒抗原构建体
WO2019161163A1 (en) * 2018-02-16 2019-08-22 The Wistar Institute Of Anatomy And Biology Epstein-barr virus nucleic acid constructs and vaccines made therefrom, and methods of using same
CN112512566A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
KR20210018206A (ko) 2018-04-03 2021-02-17 사노피 항원성 호흡기 세포융합 바이러스 폴리펩타이드
WO2020030654A1 (en) * 2018-08-07 2020-02-13 ETH Zürich Polypeptides self-assembling into nanoparticles
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
CN110922488A (zh) * 2019-11-08 2020-03-27 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种含EB病毒gp350的自组装纳米颗粒及制备方法和应用
CN111154803B (zh) * 2020-01-10 2022-07-22 新乡医学院 一种重组EBV gHgL免疫原的制备方法及其应用
EP4103160B1 (en) * 2020-02-13 2024-06-26 ETH Zurich Nanoparticles encapsulating small molecules
CN112023035A (zh) * 2020-04-07 2020-12-04 中国医学科学院医学生物学研究所 一种以SARS-CoV-2病毒S蛋白RBD区为抗原的纳米疫苗及其制备
EP4132478A1 (en) 2020-04-09 2023-02-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
EP4132572A1 (en) * 2020-04-10 2023-02-15 Vanderbilt University Recombinant vaccines and methods of use thereof
WO2021246740A1 (ko) * 2020-06-01 2021-12-09 (주)인테라 엔캡슐린 기반 백신 생산을 위한 재조합 발현 벡터 및 이의 제조방법
US12071633B2 (en) * 2020-10-13 2024-08-27 Kriya Therapeutics, Inc. Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
EP4232076A1 (en) 2020-10-20 2023-08-30 The Chancellor, Masters and Scholars of The University of Oxford Methods and compositions for treating epstein barr virus-associated cancer
CN112521511B (zh) * 2020-12-07 2023-03-14 中山大学 一种含EB病毒gB蛋白的自组装纳米颗粒及其制备方法与应用
AU2022208435A1 (en) 2021-01-18 2023-08-10 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
CN112778404B (zh) * 2021-01-28 2022-11-29 中山大学 一种含EB病毒gHgL蛋白的自组装纳米颗粒及其制备方法与应用
CN113144187B (zh) * 2021-01-28 2024-03-22 安徽智飞龙科马生物制药有限公司 一种含EB病毒gHgLgp42蛋白的自组装纳米颗粒及其制备方法与应用
CN113372440B (zh) * 2021-05-18 2022-08-23 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种识别EB病毒gH糖蛋白的单克隆抗体及其应用
WO2023192949A2 (en) * 2022-03-30 2023-10-05 Novavax, Inc. Compositions and methods for inducing an immune response against epstein-barr virus
WO2024130015A1 (en) * 2022-12-16 2024-06-20 The Cleveland Clinic Foundation Sfts virus vaccines
WO2024163327A1 (en) * 2023-01-30 2024-08-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epstein-barr virus glycoprotein 42 immunogens for vaccination and antibody discovery
CN117106102B (zh) * 2023-10-23 2024-02-06 中国医学科学院医学生物学研究所 肠道病毒多抗原表位融合蛋白、基因、疫苗及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
CA2462455C (en) 2001-10-01 2012-07-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of a preventive vaccine for filovirus infection in primates
US20050108791A1 (en) 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
EP1504037B1 (en) 2002-05-10 2009-12-30 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
GB0319797D0 (en) 2003-08-26 2003-09-24 Leuven K U Res & Dev Particle size reduction of poorly soluble drugs
WO2007032241A1 (ja) 2005-09-12 2007-03-22 Japan Science And Technology Agency 微粒子－タンパク質複合体およびその作製方法、半導体装置、蛍光標識方法
AU2007224034B2 (en) 2006-03-07 2012-03-29 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
MX2009007106A (es) 2006-12-29 2010-04-30 Inst Pasteur Of Shanghai Lentivirus pseudotipificado con hemaglutinina de influenza y metodos de uso.
EP3040082A1 (en) 2007-05-31 2016-07-06 Statens Serum Institut Influenza vaccines
WO2008157419A2 (en) 2007-06-13 2008-12-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic peptides of influenza virus
EP2190472A2 (en) 2007-08-20 2010-06-02 Fraunhofer USA, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
JP5543921B2 (ja) * 2007-10-15 2014-07-09 コリドン ピーティーワイ リミテッド 免疫応答をモジュレートするための発現系
CA2713879C (en) 2008-02-01 2020-01-07 Alpha-O Peptides Ag Self-assembling peptide nanoparticles useful as vaccines
JP5382489B2 (ja) 2008-03-29 2014-01-08 国立大学法人 奈良先端科学技術大学院大学 円偏光発光性ナノ微粒子
US20110177122A1 (en) 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
AU2010234849B2 (en) 2009-03-30 2017-06-22 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
US9764012B2 (en) * 2009-04-01 2017-09-19 University Of Miami Vaccine compositions and methods of use thereof
RU2579903C2 (ru) 2009-09-22 2016-04-10 Медикаго Инк. Способ получения вирусоподобных частиц растений
US20120219584A1 (en) 2009-10-05 2012-08-30 The United States Of America As Represented By The Secretary, Department Of Health Protection against pandemic and seasonal strains of influenza
US20120315270A1 (en) * 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
WO2011102900A1 (en) 2010-02-18 2011-08-25 Technovax, Inc. Universal virus-like particle (vlp) influenza vaccines
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
WO2013044203A2 (en) * 2011-09-23 2013-03-28 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES Novel influenza hemagglutinin protein-based vaccines
WO2015054639A1 (en) 2013-10-11 2015-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epstein-barr virus vaccines
ES2924721T3 (es) 2014-05-27 2022-10-10 Us Health Trímeros de la región del tallo de la hemaglutinina estabilizada de la influenza y usos de los mismos
EP3177720B1 (en) 2014-08-08 2021-09-22 VLP Therapeutics, Inc. Virus like particle comprising modified envelope protein e3
SG11201705264WA (en) 2014-12-31 2017-07-28 The Usa As Represented By The Secretary Detp Of Health And Human Services Novel multivalent nanoparticle-based vaccines
IL303650B1 (en) 2016-09-02 2024-10-01 Us Health Stable group 2 trimers from the stem region of influenza hemagglutinin and their uses

Also Published As

Publication number Publication date
EP3906939A1 (en) 2021-11-10
US20200330587A1 (en) 2020-10-22
WO2015054639A1 (en) 2015-04-16
US12005115B2 (en) 2024-06-11
EP3054971B1 (en) 2021-03-10
US20160303224A1 (en) 2016-10-20
CN105792842A (zh) 2016-07-20
CN105792842B (zh) 2020-06-02
US10744199B2 (en) 2020-08-18
EP3054971A1 (en) 2016-08-17

Similar Documents

Publication Publication Date Title
BR112016007868A2 (pt) vacinas contra o vírus de epstein-barr
CL2018002825A1 (es) Vacuna contra vrs
BR112019007433A2 (pt) sistemas de replicon de vírus recombinante e usos dos mesmos
BR112017014219A2 (pt) vacinas à base de nanopartículas multivalentes
BR112018011122A2 (pt) antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos
BR112018008090A2 (pt) vacina de vírus do herpes simplex.
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
BR112018013930A2 (pt) vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
BR112019004189A2 (pt) trímeros estabilizados da região de tronco da hemaglutinina do vírus influenza grupo 2 e usos dos mesmos
BR112018011073A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização
CR20140565A (es) Proteínas de fusión de interleuquina 10 y usos de las mismas
BR112012005713A2 (pt) vacinas direcionadas a célula langerhans.
CY1123403T1 (el) Τροποποιημενα κυτταρα ξενιστες και χρησεις αυτων
BR112015006763B1 (pt) Constructo de ácido nucleico, vetor de transferência plasmídico, partículas de vírus mv-chik, composições, uso da composição, uso das partículas de vírus mv-chik e processo para resgatar vírus do sarampo (mv) recombinante
WO2015052543A3 (en) Malaria vaccination
CY1124707T1 (el) Συνθεσεις και μεθοδοι για την επαγωγη ενισχυμενης ανοσοαποκρισης με χρηση φορεων ιων poxvirus (ευλογοϊων)
BR112019001115A2 (pt) proteínas de biofusão como vacinas anti-malária
WO2015059714A8 (en) A viral vaccine and methods of manufacture thereof
BR112018017174A2 (pt) conjugados de aminoácido e peptídeo e processo de conjugação
CY1124079T1 (el) Αποτελεσματικη επιλεκτικοτητα των ανασυνδυασμενων πρωτεϊνων
EA201890187A1 (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
MX2019007924A (es) Vacunas contra la influenza.
WO2015041924A8 (en) Recombinant respiratory syncytial virus (rsv) and vaccines

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122024015865-5 PROTOCOLO 870240065550 EM 02/08/2024 12:06.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]